Research
Search
Close
LU Yan
- Doctoral Supervisor, Researcher
- Department: Endocrinology and Metabolism
- Research Area: Internal Medicine (Endocrinology and Metabolism)
- Research Interests: Pathogenesis of metabolic-dysfunction associated steatohepatitis (MASH)
- Contact: luyan5011@shsmu.edu.cn
- Undergraduate and MD from Anhui Medical University, 2001 - 2006
- PhD from Shanghai Jiao Tong University School of Medicine, 2006 - 2011
- Li B, Yang Z, Mao F, Gong W, Su Q, Yang J, Liu B, Song Y, Jin J, Lu Y#. Downregulation of microRNA-145a-5p promotes steatosis-to-NASH progression through upregulation of Nr4a2. J Hepatol. 2023 Nov;79(5):1096-1109. doi: 10.1016/j.jhep.2023.06.019.
- Zhou B, Luo Y, Ji N, Hu C, Lu Y. Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis. Nat Metab. 2022 Sep;4(9):1185-1201. doi: 10.1038/s42255-022-00627-4.
- Liu B, Xiang L, Ji J, Liu W, Chen Y, Xia M, Liu Y, Liu W, Zhu P, Jin Y, Han Y, Lu J, Li X, Zheng M, Lu Y. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. J Clin Invest. 2021 Oct 15;131(20):e144801. doi: 10.1172/JCI144801.
- Wu L, Jiao Y, Li Y, Jiang J, Zhao L, Li M, Li B, Yan Z, Chen X, Li X, Lu Y. Hepatic Gadd45β promotes hyperglycemia and glucose intolerance through DNA demethylation of PGC-1α. J Exp Med. 2021 May 3;218(5):e20201475.
- Zhou B, Jia L, Zhang Z, Xiang L, Yuan Y, Zheng P, Liu B, Ren X, Bian H, Xie L, Li Y, Lu J, Zhang H, Lu Y. The Nuclear Orphan Receptor NR2F6 Promotes Hepatic Steatosis through Upregulation of Fatty Acid Transporter CD36. Adv Sci (Weinh). 2020 Sep 21;7(21):2002273. doi: 10.1002/advs.202002273.
- [Lu Yan, Li Xiaoying, Zheng Minghua, Chen Ying, Zhou Bing, Xiang Liping] (2022), “Application of Sparcl1 in the diagnosis of NASH”, CN111537719B, ZL 202010499690.5
- [Lu Yan, Zhou Bing, Luo Yunchen] (2023), “Application of a RNA targeting IGF2BP2 in the treatment of NASH”, CN114010652B, ZL202111359225.2
- [Lu Yan, Zhou Bing, Bianhua, Li Xiaoying] (2023), “Application of a protein in the treatment of obesity-related NAFLD”, CN114516910B, ZL202011300266.X
- [Lu Yan, Zhou Bing, Bianhua, Li Xiaoying] (2023), “Application of a protein in the treatment of obesity-related NAFLD”, CN114516910B, ZL202011300266.X. This patent has been transferred to a biomedical company.
